During your consultation, our experienced team will carefully review your health history, weight loss goals, and any existing conditions to determine if GLP-1 therapy is the right fit for you
B12 deficiency is surprisingly common in the general population, and the metabolic changes triggered by tirzepatide can amplify that deficiency
Approximately 1 in 10 patients with NCIS experienced a recurrent ischemic stroke within one year, with most events concentrated soon after discharge
Lifestyle, work schedule, eating patterns, and prior medication experience all influence outcomes
Pancreatitis in Patients Receiving Tirzepatide (Mounjaro): A One-Year Audit in a UK District General Hospital
Small interfering RNA to reduce lipoprotein(a) in cardiovascular disease